ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Press
Craif Expands miSignal Scan and miSignal Navi to 10 Cancer Types, Adding Kidney, Bladder, and Prostate
2025.07.07

Those 10 cancer types together account for about 80 percent of cancer deaths in Japan, per national statistics.

TOKYO, July 6, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, will begin offering new 10-cancer-type models of its urine cancer risk test, miSignal Scan, and its cancer-focused genetic test, miSignal Navi, in Japan on July 7, 2025. The new models add kidney cancer, bladder cancer, and prostate cancer to the seven cancer types already covered.

Together, those 10 cancer types account for about 80 percent of all cancer deaths in Japan. That figure describes how much of Japan's cancer mortality falls within the cancer types the test now addresses. It does not measure how many cancers, or how many cancer deaths, the test detects or prevents. The new models also report each cancer type separately rather than as a single combined result.

Prices are unchanged from the current seven-cancer-type version.

Source of the 80 percent figure

The figure is based on Cancer Statistics, published by the National Cancer Center Japan Cancer Information Service from Ministry of Health, Labour and Welfare Vital Statistics, and excludes hematologic malignancies. Mortality rates are from the National Cancer Center Japan website, 2021 data.

The 10 cancer types

miSignal Scan and miSignal Navi test for cancers including kidney cancer, bladder cancer, prostate cancer, pancreatic cancer, colorectal cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, and ovarian cancer.

Prostate cancer applies to men only, and breast cancer and ovarian cancer apply to women only. This applies to both miSignal Scan and miSignal Navi, so each person is assessed for up to nine cancer types: eight for men and nine for women.

Why these three cancer types were added

The three added cancer types share one problem: they produce few or no symptoms in the early stages, which makes them hard to find.

  • Kidney cancer. More than 60 percent are found incidentally, while the person has no symptoms, citing the EAU Guidelines on Renal Cell Carcinoma (2024). Craif describes dialysis, high blood pressure, and obesity as risk factors.
  • Bladder cancer. About 80 percent of patients are found by way of painless blood in the urine, citing Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022). Craif adds that blood in urine often has a temporary cause, so bladder cancer is easy to overlook.
  • Prostate cancer. The most common cancer by incidence among men in Japan, rising sharply from age 50, citing National Cancer Center Japan Cancer Statistics. Craif describes family history, obesity, and lifestyle as associated factors.

The new models widen the opportunity for people at risk from these largely asymptomatic cancers to see their risk for each cancer type individually, without an invasive procedure.

Product details

The miSignal Scan, 10-cancer-type model shows current cancer risk for up to 10 cancer types individually and from Stage 1. Craif describes it as the world's first urine-based cancer risk test using microRNA and AI. It combines large-scale urine data with AI.

miSignal Navi, a 10-cancer-type model, is a saliva-based genetic test. Developed by cancer research specialists, it gives advice from a single test on cancer prevention measures suited to the individual's constitution, as a first step in a lifelong approach to cancer.

Pricing

  • miSignal Scan, single test: 69,300 yen, tax included.
  • miSignal Scan, subscription: 64,300 yen, tax included, which Craif describes as 5,000 yen below the single-test price. Cycles of 4, 6, or 12 months can be selected.
  • miSignal Navi: 28,600 yen, tax included.

A commitment to better cancer outcomes

Since its founding, Craif has worked toward what it calls a society where people live out their natural lifespan, using urinary microRNA for very early cancer detection. Since miSignal Scan launched in 2022, its use has spread to more than 1,200 medical institutions, pharmacies, corporate programs, and e-commerce channels. In joint research, Craif works with more than 50 university hospitals and cancer research centers across Japan and has presented more than 60 research findings to date.

The new models were developed as part of its continuing work to cover a broader range of cancer types, and Craif will keep updating the miSignal series models.

About the miSignal series

  • miSignal Scan: assesses cancer risk using microRNA and AI analysis, which Craif describes as high precision.
  • miSignal Lite: a more accessible cancer risk assessment.
  • miSignal Navi: a cancer-focused genetic test.
  • miSignal Check: monitors DNA damage to support prevention.

All four use only a urine or saliva sample, so collection is non-invasive. Craif presents them together as a way to understand constitutional risk, day-to-day DNA damage, and current risk.

The miSignal series is not a medical device. It determines risk by statistically analyzing the data. It does not replace a diagnosis, as a medical act, of whether a person has cancer, and a result of low risk does not mean that cancer is absent or that the person will not develop cancer in the future.

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Media contact

press_us@craif.com